within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB06_Ganciclovir;

model Ganciclovir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.3666666666666655e-06,
    adminDuration = 600,
    adminMass = 350 / 1000000,
    adminCount = 1,
    Vd = 0.00069,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00061,
    k12 = 1.3333333333333334e-06,
    k21 = 1.3333333333333334e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ganciclovir</td></tr><tr><td>ATC code:</td><td>J05AB06</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>350</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.69</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.6</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ganciclovir is an antiviral medication used primarily to treat and prevent cytomegalovirus (CMV) infections, especially in immunocompromised patients such as those with HIV/AIDS or transplant recipients. It is an approved drug and is still widely used in clinical practice for CMV infections.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters for adult immunocompetent volunteers following a single intravenous dose of 5 mg/kg.</p><h4>References</h4><ol><li><p>Nguyen, T, et al., &amp; Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. <i>Antimicrobial agents and chemotherapy</i> 65(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02254-20\">10.1128/AAC.02254-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33318012/\">https://pubmed.ncbi.nlm.nih.gov/33318012</a></p></li><li><p>Selby, PR, et al., &amp; Roberts, JA (2023). Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Antimicrobial agents and chemotherapy</i> 67(3) e0155022–None. DOI:<a href=\"https://doi.org/10.1128/aac.01550-22\">10.1128/aac.01550-22</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36815858/\">https://pubmed.ncbi.nlm.nih.gov/36815858</a></p></li><li><p>Li, S, et al., &amp; Wang, Y (2020). Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children. <i>Frontiers in pharmacology</i> 11 614164–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2020.614164\">10.3389/fphar.2020.614164</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33536921/\">https://pubmed.ncbi.nlm.nih.gov/33536921</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AB06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ganciclovir;
